Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724199 · ClinicalTrials.gov registry record · Phase 3
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
A Phase 3 study of Atopic Dermatitis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 746
- Enrollment target
- 20
- Study locations
NCT05724199 is a Phase 3 study of Atopic Dermatitis that has completed, run by Amgen. The registered enrollment target is 746 participants, above the 604-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT05724199, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 746 participants
- Enrollment target
- 20
- Study locations
Study Summary
The coprimary objectives of the study are to: * evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). * evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Keck Medicine of University of Southern California - Los Angeles
- Wallace Medical Group Inc - Los Angeles
- Antelope Valley Clinical Trials - Palmdale
- University of California at Davis Medical Center - Sacramento
- Kaiser Permanente South Sacramento Medical Center - Sacramento
- Acclaim Clinical Research - San Diego
- Kaiser Permanente Medical Center - Oakland - San Francisco
- Kaiser Permanente Medical Center - San Francisco - San Francisco
- Synergy Dermatology - San Francisco
Arizona
- Medical Dermatology Specialists - Phoenix
- Southwest Skin Specialists - Phoenix
- US Dermatology Partners Sun City West - Sun City West
Florida
- TrueBlue Clinical Research - Tampa
- Olympian Clinical Research - Tampa - Tampa
Georgia
- Atlanta Dermatology, Vein and Research Center, PC - Alpharetta
- Divine Dermatology and Aesthetics - Atlanta
Alabama
- The University of Alabama at Birmingham - Birmingham
Arkansas
- Arkansas Research Trials, LLC - North Little Rock
Illinois
- NorthShore University HealthSystem - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 746 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2024-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05724199
The ClinicalTrials.gov registry entry for NCT05724199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 746 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 604-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (24% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05724199 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05724199 about?
NCT05724199 is a clinical study titled "A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)". The coprimary objectives of the study are to: * evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment fo...
What is the current status of trial NCT05724199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 746 participants. The study started on 2023-02-21. Estimated completion is 2024-12-04.
What conditions does trial NCT05724199 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05724199?
The interventions under investigation include: Placebo (OTHER), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT05724199?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05724199 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.